CBIO Q3 2024 Earnings — Crescent Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

CBIOCrescent Biopharma, Inc.

$345M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$8,130

Operating Income

-$11M

Net Income

-$10M

EPS (Diluted)

$-0.15

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

$19M

Free Cash Flow

$19M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$16M

Total Liabilities

$4M

Stockholders' Equity

$11M

Cash & Equivalents

$14M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$8,130	-$269,937	+97.0%
Operating Income	-$11M	-$10M	-14.5%
Net Income	-$10M	-$9M	-6.8%